- Microbot Medical (MBOT, Financial) enhances its commercial leadership team with strategic appointments.
- Allison Rosefort joins as Vice President of Marketing, specializing in healthcare marketing.
- LIBERTY® system's FDA decision expected in Q2 2025, paving the way for potential launch.
Microbot Medical Inc. (NASDAQ: MBOT), a leading developer in the medical technology sector, has announced the strengthening of its commercial leadership team. This strategic move comes as the company prepares for the anticipated FDA decision on its LIBERTY® Endovascular Robotic System in the second quarter of 2025.
The company has appointed Allison Rosefort as Vice President of Marketing. Rosefort, a seasoned marketing executive with over 15 years of experience, brings a proven track record of driving double-digit revenue growth. Her role will focus on downstream marketing and brand management strategies, vital for the commercialization of the LIBERTY® system. Prior to joining Microbot Medical, she held senior positions at Topcon Healthcare and Integra LifeSciences.
Additionally, Lisa Dobbins has been named the Director of Human Resources, complementing the recent addition of Paul Mullen as Vice President of Sales. These appointments are strategically timed to align with the forthcoming FDA decision, positioning the company for a swift commercial launch upon potential approval.
Harel Gadot, CEO of Microbot Medical, expressed confidence in the newly formed leadership team, emphasizing readiness for the LIBERTY® system's launch post-FDA clearance. Currently, LIBERTY® is under investigational status and is not yet available for sale in the U.S.
